Barclays PLC increased its stake in LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) by 82.6% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 30,057 shares of the company's stock after buying an additional 13,594 shares during the quarter. Barclays PLC owned 0.11% of LENZ Therapeutics worth $867,000 at the end of the most recent quarter.
Other institutional investors also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. bought a new stake in LENZ Therapeutics in the fourth quarter worth about $29,000. KLP Kapitalforvaltning AS purchased a new stake in shares of LENZ Therapeutics during the 4th quarter worth approximately $46,000. SG Americas Securities LLC raised its holdings in shares of LENZ Therapeutics by 20.7% in the 4th quarter. SG Americas Securities LLC now owns 5,458 shares of the company's stock worth $158,000 after purchasing an additional 935 shares during the period. China Universal Asset Management Co. Ltd. purchased a new position in LENZ Therapeutics in the fourth quarter valued at approximately $168,000. Finally, Wells Fargo & Company MN grew its holdings in LENZ Therapeutics by 27.3% during the fourth quarter. Wells Fargo & Company MN now owns 7,504 shares of the company's stock valued at $217,000 after purchasing an additional 1,608 shares during the period. Institutional investors own 54.32% of the company's stock.
Analysts Set New Price Targets
LENZ has been the topic of a number of recent research reports. Piper Sandler initiated coverage on LENZ Therapeutics in a research report on Monday, April 14th. They set an "overweight" rating and a $51.00 price target on the stock. Citigroup increased their target price on shares of LENZ Therapeutics from $44.00 to $47.00 and gave the stock a "buy" rating in a research report on Thursday, March 20th. HC Wainwright reissued a "buy" rating and issued a $38.00 price target on shares of LENZ Therapeutics in a research report on Wednesday, April 16th. Finally, TD Cowen started coverage on shares of LENZ Therapeutics in a report on Tuesday, March 18th. They issued a "buy" rating and a $60.00 price objective for the company. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, LENZ Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $46.60.
View Our Latest Research Report on LENZ
LENZ Therapeutics Stock Down 1.4 %
Shares of LENZ opened at $29.10 on Tuesday. LENZ Therapeutics, Inc. has a twelve month low of $14.42 and a twelve month high of $38.93. The stock has a market cap of $801.56 million, a PE ratio of -6.10 and a beta of 0.41. The business's 50-day moving average price is $24.21 and its 200-day moving average price is $27.30.
LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last announced its quarterly earnings results on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.04). Analysts expect that LENZ Therapeutics, Inc. will post -2.18 earnings per share for the current fiscal year.
LENZ Therapeutics Profile
(
Free Report)
LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Further Reading
Want to see what other hedge funds are holding LENZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider LENZ Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LENZ Therapeutics wasn't on the list.
While LENZ Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
